25934-52-5

Basic information

• Product Name: 3-CyclopropylMethoxy-4-Hydroxybenzaldehyde
• Synonyms: 3-CyclopropylMethoxy-4-Hydroxybenzaldehyde;alpha-Cyclopropylvanillin;Benzaldehyde, 3-(cyclopropylmethoxy)-4-hydroxy-;4-(cyclopropylmethoxy)-3-hydroxybenzaldehyde
• CAS NO: 25934-52-5
• Molecular Formula: C₁₁H₁₂O₃
• Molecular Weight: 192.21118
• Product Categories: Roflumilast interemdiate
• Mol File: 25934-52-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-CyclopropylMethoxy-4-Hydroxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CyclopropylMethoxy-4-Hydroxybenzaldehyde(25934-52-5)
• EPA Substance Registry System: 3-CyclopropylMethoxy-4-Hydroxybenzaldehyde(25934-52-5)

Safety Data

• Hazardous Substances Data: 25934-52-5(Hazardous Substances Data)

Usage

Description

3-Cyclopropylmethoxy-4-hydroxybenzaldehyde is an organic compound characterized by the presence of a cyclopropylmethoxy group at the 3-position and a hydroxyl group at the 4-position of a benzene ring. It features a benzaldehyde functional group, which is an aldehyde attached to a benzene ring. 3-Cyclopropylmethoxy-4-hydroxybenzaldehyde is known for its potential applications in various chemical and pharmaceutical processes.

Uses

Used in Pharmaceutical Industry:
3-Cyclopropylmethoxy-4-hydroxybenzaldehyde is used as a reactant in the preparation of ethyl (alkoxy)(cyclopropylmethoxy)-4-hydroxy-3-quinolinecarboxylates. These quinolinecarboxylate derivatives are of interest in the pharmaceutical industry due to their potential as therapeutic agents, particularly in the development of new drugs targeting various diseases and conditions.
In the synthesis of these ethyl (alkoxy)(cyclopropylmethoxy)-4-hydroxy-3-quinolinecarboxylates, 3-cyclopropylmethoxy-4-hydroxybenzaldehyde serves as a key intermediate, contributing to the formation of the desired quinolinecarboxylate structure. The cyclopropylmethoxy group imparts unique properties to the final product, which may enhance its pharmacological activity, selectivity, and bioavailability.
Overall, 3-Cyclopropylmethoxy-4-hydroxybenzaldehyde plays a crucial role in the development of novel pharmaceutical compounds, particularly in the area of quinolinecarboxylate-based drugs, offering potential benefits in the treatment of various medical conditions.

Upstream product

• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 
• 1381886-14-1 4-(benzyloxy)-3-(cyclopropylmethoxy)benzaldehyde 

Downstream Products

• 162401-62-9 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid 
• 672883-68-0 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoyl chloride 
• 151103-09-2 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzaldehyde 

Relevant articles and documents

Novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE (phosphodiesterase) 4 inhibitors

The invention discloses novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE (phosphodiesterase) 4 inhibitors. The inhibitors are compounds represented in a general formula I or a general formula II, prodrugs thereof, pharmaceutically usable salts thereof or solvates thereof, wherein R is independent methyl (Me-) or difluoromethyl (CF2H-); R is independent H, Me or Et; R is independent H, MeO or Cl; CnH(2n+2) is alkyl, and N is larger than or equal to 2; a substance shown in the specification is a substituted benzene ring or pyridine ring; X is C or N; Y is C or N. The novel 3-cyclopropylmethoxy-4-alkoxybenzamide PDE 4 inhibitors have the advantages of high in-vitro enzyme inhibition activity, capability of selective application to PDE4 and good anti-inflammation effect and anti-depression effect.